Bactiguard AB
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions that lower the risk of infections, increase patient safety and reduce the use of antibiotics. Our own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevents common infections in the urinary tract, the bloodstream and the respiratory tract. HAIs are infections that patients acquire during hospital care or when seeking other kinds of healthcare. It is currently the third most common cause of death in high income countries. Our technology significantly reduces the risk of HAIs as it lowers the risk of infections by 35-90. Our daily activities at Bactiguard are focused on preventing healthcare associated infections. This is how we contribute to achieving the UN’s global goals.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2005
About us
Our technology prevents bacterial adhesion and biofilm formation on medical devices. We offer this technology through license agreements and our own BIP (Bactiguard Infection Protection) product portfolio. Urinary catheters with Bactiguard’s coating are market leading in the USA and Japan through our license partner BD.
Our own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevents common infections in the urinary tract, the bloodstream and the respiratory tract.
In February 2020 we acquired the Malaysian medical device company Vigilenz with a portfolio of products that comprise surgical sutures, mesh, wound wash, dressings and orthopaedic trauma implants. This acquisition boosts our position in infection prevention and wound care, and gives us greater innovation and product development capacity and expertise.
HAIs result in antibiotics being prescribed, which increases the risk of antibiotic resistance. The World Health Organization, WHO, has stated that antibiotic resistance is a global crisis that must be tackled urgently and that infection prevention is crucial to this work. This is why our mission and technology are so important in saving lives.
Mission and Vision
To eliminate infections in order to:
- Increase patient safety and save lives.
- Reduce the use of antibiotics and limit the spread of multi-resistant bacteria.
- Reduce healthcare costs.
We save lives by developing and offering infection prevention solutions that reduce the risk of infections.
Our core valuesEverything we do in our daily operations is guided by:
- Long-term partnership
- Trust and responsibility
- Creativity
- Responsiveness
- Resourcefulness
… and is embraced by empathy, respect and communication.
We Save Lives!
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions that lower the risk of infections, increase patient safety and reduce the use of antibiotics.
Our technology prevents bacterial adhesion and biofilm formation on medical devices. We offer this technology through license agreements and our own BIP (Bactiguard Infection Protection) product portfolio. Urinary catheters with Bactiguard’s coating are market leading in the USA and Japan through our license partner BD.
Our own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevents common infections in the urinary tract, the bloodstream and the respiratory tract.
In February 2020 we acquired the Malaysian medical device company Vigilenz with a portfolio of products that comprise surgical sutures, mesh, wound wash, dressings and orthopaedic trauma implants. This acquisition boosts our position in infection prevention and wound care, and gives us greater innovation and product development capacity and expertise.
Our technology plays an important role in reducing the risk of healthcare associated infections (HAIs). This technology has been tested in more than 40 clinical studies including 100,000 patients. It is effective, safe and can be used over a long period of time in the body.
HAIs are infections that patients acquire during hospital care or when seeking other kinds of healthcare. It is currently the third most common cause of death in high income countries. Our technology significantly reduces the risk of HAIs as it lowers the risk of infections by 35-90%.
HAIs result in antibiotics being prescribed, which increases the risk of antibiotic resistance. The World Health Organization, WHO, has stated that antibiotic resistance is a global crisis that must be tackled urgently and that infection prevention is crucial to this work. This is why our mission and technology are so important in saving lives.
We Contribute to UN’s Global Goals
Our unique technology enables us to contribute to the UN’s Global Goal 3: Good health and well-being. The UN has stated that good health is essential for people to be able to realise their full potential and contribute to social development.
According to WHO, antibiotic resistance is a threat to achieving the UN’s global sustainability goals. The lack of effective treatments for TBC, pneumonia and urinary tract infections poses a serious threat to global public health.
Our unique technology enables us to contribute to the UN’s Global Goal 3: Good health and well-being. The UN has stated that good health is essential for people to be able to realise their full potential and contribute to social development. The aim is to end the epidemics of AIDS, tuberculosis and malaria by 2030 and to combat hepatitis, waterborne diseases and other contagious
diseases. This goal is at risk if we do not succeed in our work to prevent healthcare associated infections.
Bactiguard’s products form an important link in the value chain for healthcare associated infections. Viral infections – for example the coronavirus – places the body’s immune system under stress, which increases the risk of secondary bacterial infections. One of the most serious bacterial infections is sepsis, which kills 11 million people every year. We offer significantly improved infection protection when using our medical devices and implants in the urinary tract, the respiratory tract and the bloodstream.